Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Sells $587,792.10 in Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSMGet Free Report) COO Mark L. Jacobson sold 7,910 shares of Axsome Therapeutics stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $74.31, for a total transaction of $587,792.10. Following the sale, the chief operating officer now owns 5,783 shares in the company, valued at approximately $429,734.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mark L. Jacobson also recently made the following trade(s):

  • On Monday, April 1st, Mark L. Jacobson sold 24,662 shares of Axsome Therapeutics stock. The shares were sold at an average price of $77.24, for a total transaction of $1,904,892.88.

Axsome Therapeutics Stock Down 1.1 %

AXSM stock opened at $73.43 on Friday. The company has a debt-to-equity ratio of 1.25, a current ratio of 3.20 and a quick ratio of 3.09. Axsome Therapeutics, Inc. has a 1-year low of $55.02 and a 1-year high of $98.40. The firm has a fifty day moving average price of $74.07 and a two-hundred day moving average price of $77.21. The firm has a market cap of $3.49 billion, a price-to-earnings ratio of -11.51 and a beta of 1.13.

Axsome Therapeutics (NASDAQ:AXSMGet Free Report) last released its earnings results on Monday, May 6th. The company reported ($1.09) earnings per share for the quarter, beating the consensus estimate of ($1.20) by $0.11. Axsome Therapeutics had a negative net margin of 118.07% and a negative return on equity of 87.17%. The firm had revenue of $75.00 million during the quarter, compared to analyst estimates of $69.91 million. Research analysts predict that Axsome Therapeutics, Inc. will post -4.7 EPS for the current year.

Hedge Funds Weigh In On Axsome Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Washington Trust Advisors Inc. acquired a new position in shares of Axsome Therapeutics during the fourth quarter valued at $26,000. EntryPoint Capital LLC acquired a new position in shares of Axsome Therapeutics during the first quarter valued at $35,000. Russell Investments Group Ltd. boosted its holdings in shares of Axsome Therapeutics by 5,550.0% during the first quarter. Russell Investments Group Ltd. now owns 791 shares of the company’s stock valued at $63,000 after acquiring an additional 777 shares during the period. Covestor Ltd boosted its holdings in shares of Axsome Therapeutics by 54,750.0% during the first quarter. Covestor Ltd now owns 1,097 shares of the company’s stock valued at $88,000 after acquiring an additional 1,095 shares during the period. Finally, Janiczek Wealth Management LLC acquired a new position in shares of Axsome Therapeutics during the first quarter valued at $97,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Wall Street Analyst Weigh In

AXSM has been the topic of a number of analyst reports. Royal Bank of Canada lifted their price objective on shares of Axsome Therapeutics from $123.00 to $128.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. Mizuho dropped their price objective on shares of Axsome Therapeutics from $109.00 to $106.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Citigroup dropped their price target on shares of Axsome Therapeutics from $127.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, May 7th. HC Wainwright restated a “buy” rating and issued a $190.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, May 7th. Finally, Guggenheim lifted their price target on shares of Axsome Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a research note on Wednesday, February 21st. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $121.92.

Read Our Latest Stock Report on Axsome Therapeutics

About Axsome Therapeutics

(Get Free Report)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

Featured Articles

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.